Patients with Crohn's disease may begin to be treated differentl

A group of scientists from the University of Washington School of Medicine (Washington University School of Medicine) proposed a new therapy for patients with inflammatory bowel disease, Crohn's disease and ulcerative colitis. They found an opportunity to block the work of one of the genes involved in the development of inflammation in the intestine. Researchers have already shown that the new therapy works in mice.

The authors, led by Thaddeus Stappenbeck (Thaddeus S. Stappenbeck) explain that the new approach is suitable for those who do not help other drugs, such as drugs that block TNF (tumor necrosis factor).

The emergence of new effective therapy can be a real salvation for those who suffer from Crohn's disease and ulcerative colitis - diseases that significantly impair the quality of life of patients.

In order to select a new approach to treatment, the researchers studied more than 1,800 biopsy specimens taken from 14 independent bases. Among the samples were fragments of tissue taken from healthy people, and samples obtained from patients.

It turned out that those who suffered from inflammatory bowel disease, problems with blood clotting were more common than in healthy people. The product of the SERPINE-1 gene was responsible for this — its expression level was 6 times higher than normal.

In experiments on mice, the authors showed that therapy using the compound MDI-2268 suppressed SERPINE-1. This in turn improved the condition of the rodents. Now scientists are planning to conduct a series of studies on patients to demonstrate the effectiveness of the therapy they found.

0 Response to "Patients with Crohn's disease may begin to be treated differentl"

Post a Comment

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel